Clinical trials: Psychosis; Acute
Acute Schizophrenia
Treatment of Acute Schizophrenia With Vitamin Therapy
Controlled studies using the orthomolecular approach have been few (Deutsch, Ananth, \& Ban, 1977). Those that were done were performed in chronic schizophrenia or in populations that included bipolar and schizoaffective…
- Trial name
- NCT00140166
- Testing
- niacinamide, pyridoxine, ascorbate
- Where
- Israel
- Volunteers
- 55 people
- Sponsor
- Beersheva Mental Health Center
Schizophrenia
Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
This is a multi-centre, open, randomized, haloperidol-referenced, 47 days two treatment sessions, parallel-group study. After screening period, eligible subjects will be entered 5 days treatment session I to compare the efficacy…
- Trial name
- NCT00859872
- Testing
- risperidone oral solution, haloperidol
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Central South University
Acute Psychotic Episode, Schizophrenia
Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia
This is an observational study describing the real-life antipsychotic treatment during the hospitalisation of the patients due to acute psychotic episode.
- Trial name
- NCT01491412
- Where
- 14 sites in Hungary, Latvia and 1 more
- Volunteers
- 503 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of flexible-doses paliperidone ER (3 to 12 mg as needed) compared with placebo over 3 weeks in patients with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00309699
- Testing
- Quetiapine, Paliperidone ER
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 493 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychosis
Immune Mechanisms of Antipsychotic Treatment Response
The aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment. The investigators will collect blood and cerebrospinal fluid samples from participants with psychosis…
- Trial name
- IMAT (NCT06687694)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- King's College London
Psychosis, Suicidal
Acceptability and Feasibility of MOL in Acute Inpatient Units
The current study aims to test the acceptability and feasibility of a psychological therapy called Method of Levels (MOL) as an intervention for people in acute psychiatric inpatient units who are experiencing psychosis and/or…
- Trial name
- NCT05377294
- Testing
- Method of Levels therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- University of Manchester
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.
- Trial name
- NCT00954122
- Testing
- Quetiapine XR (Seroquel XR)
- Where
- 2 sites in Malaysia
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Schizophrenia
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
- Trial name
- NCT00265551
- Testing
- SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg)
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term…
- Trial name
- PEARL 3 (NCT00790192)
- Testing
- Lurasidone, Quetiapine XR
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 488 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
- Trial name
- NCT00694707
- Testing
- Cariprazine, Risperidone
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 732 people
- Sponsor
- Forest Laboratories
Schizophrenia and Other Psychotic Disorders, Harm Reduction
CBD Cigarettes Instead of Normal Cigarettes as Innovative Treatment for Schizophrenia
Interventional study using Cannabidiol containing cigarettes as replacement of usual cigarettes Reduction of enforcement measures, improved acute treatment, harm reduction, and improvement of psychotic symptoms
- Trial name
- NCT04700930
- Testing
- CBD-Cigarettes
- Where
- Switzerland
- Volunteers
- 31 people
- Sponsor
- Psychiatric Hospital of the University of Basel
Schizophrenia
Study Evaluating Vabicaserin in Subjects With Schizophrenia
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
- Trial name
- NCT00563706
- Testing
- vabicaserin, risperidone
- Where
- 33 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Pfizer
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
This study is a phase III, multicenter, randomized, double-blind, active-controlled, non-inferiority trial designed to assess the efficacy and safety of Brexpiprazole in the Treatment of Adults With Acute Schizophrenia.
- Trial name
- NCT03874494
- Testing
- Brexpiprazole, Aripiprazole
- Where
- China
- Volunteers
- 371 people
- Sponsor
- Otsuka Beijing Research Institute
Delirium, Agitated Behavior
Trial of Safety Nets In Hospitalized Patients
This study compared standard hospital restraints to a newer safety net restraint system to compare them for acceptability, tolerance, duration of restrain, length of stay in the hospital, and satisfaction of MD, nurse, and…
- Conditions
- Delirium, Agitated Behavior, Alcohol Withdrawl, Acute Confusional State
- Trial name
- NCT00409370
- Testing
- SOMA safe enclosure
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Griffin Hospital
Schizophrenia
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
- Trial name
- NCT05011669
- Testing
- Lurasidone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.
This is a screening study aimed at estimating the frequency of antipsychotic non-compliance in patients with a history of schizophrenia or other psychotic disorder admitted to an inpatient psychiatric unit.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786369
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Northwell Health
Healthy
N-acetylcysteine Effects on Tetrahydrocannabinol
The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC).
- Trial name
- NCT02335060
- Testing
- Delta-9-THC, N-acetylcysteine
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Yale University
Acute Schizophrenia
A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia
This is a randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), active-controlled…
- Trial name
- NCT00350467
- Testing
- ER OROS paliperidone and Olanzapine
- Where
- 7 sites in China
- Volunteers
- 288 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.